Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

1095506

USP

Carbidopa

United States Pharmacopeia (USP) Reference Standard

Sinonimo/i:

(S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropionic acid monohydrate

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

400 MG
CHF 391.00

CHF 391.00

Check Cart for Availability
Richiedi un ordine bulk
Tutte le immagini(1)

Scegli un formato

Cambia visualizzazione
400 MG
CHF 391.00

About This Item

Formula empirica (notazione di Hill):
C10H14N2O4 · H2O
Numero CAS:
38821-49-7
Peso molecolare:
244.24
Numero MDL:
MFCD00889211
Codice UNSPSC:
41116107
ID PubChem:
329749233
NACRES:
NA.24

CHF 391.00

Check Cart for Availability
Richiedi un ordine bulk

Grado

pharmaceutical primary standard

Famiglia di API

carbidopa

Produttore/marchio commerciale

USP

applicazioni

pharmaceutical (small molecule)

Formato

neat

Stringa SMILE

O.C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O

InChI

1S/C10H14N2O4.H2O/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6;/h2-4,12-14H,5,11H2,1H3,(H,15,16);1H2/t10-;/m0./s1
QTAOMKOIBXZKND-PPHPATTJSA-N

Informazioni sul gene

human ... DDC(1644)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Carbidopa USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Carbidopa and Levodopa Extended-Release Tablets
  • Carbidopa and Levodopa Orally Disintegrating Tablets
  • Carbidopa and Levodopa Tablets

Risultati analitici

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Altre note

Sales restrictions may apply.

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H302,H319

Classi di pericolo

Acute Tox. 4 Oral - Eye Irrit. 2

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 7

1 of 7

USP

USP

1361010

Levadopa Related Compound A

Levodopa European Pharmacopoeia (EP) Reference Standard

L0400000

Levodopa

Levodopa Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1271

Levodopa

Levodopa British Pharmacopoeia (BP) Reference Standard

BP213

Levodopa

L-Dopa-(phenyl-d3) ≥98 atom % D, ≥98% (CP)

Sigma-Aldrich

333786

L-Dopa-(phenyl-d3)

3,4-Dihydroxy-L-phenylalanine ≥98% (TLC)

Sigma-Aldrich

D9628

3,4-Dihydroxy-L-phenylalanine

Dopamine hydrochloride

Sigma-Aldrich

H8502

Dopamine hydrochloride

Q. Alan Xu, Timothy L. Madden
Analytical Methods for Therapeutic Drug Monitoring and Toxicology, 80-80 (2011)
Mohseni Mehran S M et al.
Journal of clinical and diagnostic research : JCDR, 7(6), 1004-1007 (2013-08-02)
According to many studies, sprouted fava beans are a rich source of levo-dihydroxy phenylalanine (L-dopa) the precursor of dopamine, and they are now being investigated for use in the management of Parkinson's disease. The addition of Carbidopa (C-dopa) can reduce
J T Hutton et al.
Neurology, 42(1 Suppl 1), 51-56 (1992-01-01)
Parkinson's disease patients treated chronically with levodopa often develop fluctuations in motor response. Motor fluctuations can be attributed in part to oscillating plasma levodopa concentrations. A controlled-release formulation containing 200 mg of levodopa and 50 mg of carbidopa provides superior
Robert A Hauser
Expert review of neurotherapeutics, 12(2), 133-140 (2012-02-01)
Levodopa (LD) remains the most effective medication to treat Parkinson's disease (PD). However, most patients develop motor fluctuations and dyskinesias with long-term LD use. It is thought that these response complications are due, at least in part, to LD's short
A Castro et al.
Neurologia (Barcelona, Spain), 20(4), 180-188 (2005-05-14)
Levodopa remains the mainstay treatment for Parkinson's disease (PD). Chronic treatment is associated with motor complications (MC) that marred the clinical benefit of levodopa. These problems and experimental data in cell cultures indicating a neurotoxic effect of levodopa have led
Visualizza tutti i documenti correlati

Questions

Reviews

No rating value

Active Filters

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.